Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1
1(33.3%)
Phase 4
1(33.3%)
N/A
1(33.3%)
3Total
Phase 1(1)
Phase 4(1)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT04451057Not ApplicableRecruiting

High Flow Nasal Cannula in Pediatric Patients After Cardiothoracic Surgery

Role: collaborator

NCT02256618Phase 1Completed

Autologous Cord Blood Cell Therapy for Neonatal Encephalopathy

Role: collaborator

NCT02455830Unknown

Cytokines Associated With Cord Blood Cell Therapy for Neonatal Encephalopathy

Role: collaborator

NCT01760967Phase 4Completed

Dexmedetomidine for Sepsis in ICU Randomized Evaluation Trial

Role: collaborator

All 4 trials loaded